A 3-week, Multi-center, Open-label, Randomized, Active-control, Parallel-group Study to Compare Effects of Nateglinide and Acarbose on Postprandial Glucose Fluctuation in Chinese Drug-naive Patients Type 2 Diabetes Mellitus.

Trial Profile

A 3-week, Multi-center, Open-label, Randomized, Active-control, Parallel-group Study to Compare Effects of Nateglinide and Acarbose on Postprandial Glucose Fluctuation in Chinese Drug-naive Patients Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2012

At a glance

  • Drugs Nateglinide (Primary) ; Acarbose
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ENERGY 2
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top